IL6 and rheumatoid arthritis: These changes remained significant in the multivariable adjustment, including disease activity as assessed by the CDAI index, which excludes phase reactants and has been proposed as the optimal index for evaluating RA activity (22), particularly in patients undergoing anti-IL6 treatment.